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Abstract
Negative regulation of the NF-kB transcription factor is essential for tissue homeostasis in response to stress and
inflammation. NF-kB activity is regulated by a variety of biochemical mechanisms including phosphorylation, acetylation,
and ubiquitination. In this study, we provide the first experimental evidence that NF-kB is regulated by SUMOylation, where
the RelA subunit of NF-kB is SUMOylated by PIAS3, a member of the PIAS (protein inhibitor of activated STAT) protein family
with E3 SUMO ligase activity. PIAS3-mediated NF-kB repression was compromised by either RelA mutant resistant to
SUMOylation or PIAS3 mutant defective in SUMOylation. PIAS3-mediated SUMOylation of endogenous RelA was induced by
NF-kB activation thus forming a negative regulatory loop. The SUMOylation of endogenous RelA was enhanced in IkBa null
as compared with wild type fibroblasts. The RelA SUMOylation was induced by TNFa but not leptomycin B mediated RelA
nuclear translocation. Furthermore, RelA mutants defective in DNA binding were not SUMOylated by PIAS3, suggesting that
RelA DNA binding is a signal for PIAS3-mediated SUMOylation. These results support a novel negative feedback mechanism
for NF-kB regulation by PIAS3-mediated RelA SUMOylation.
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Introduction
NF-kB is a transcription factor that mediates cellular response
to inflammation, immune response, and stress [1]. Deregulation
of NF-kB is one of the common features in many pathological
disorders including inflammatory diseases and cancer. NF-kBi s
a dimeric protein which can be comprised of a variety of
combinations of Rel family DNA binding proteins including
RelA (p65), RelB, c-Rel, p50, and p52. A heterodimer of RelA
and p50 is the most common combination in the canonical NF-
kB signaling pathway. In unstimulated cells, NF-kB is held in
check by the inhibitor of NF-kB( I kBa) which sequesters NF-kB
in the cytoplasm and prevents NF-kB DNA binding. Upon
stimulation, IkBa is phosphorylated by IkB kinases, leading to its
degradation. The degradation of IkBa allows the free NF-kBt o
translocate to the nucleus where it functions as a transcription
factor to induce the expression of proinflammatory cytokines,
chemokines, and factors for cell proliferation and survival [2].
Aberrant activation of NF-kB is detrimental to the host and
may lead to a variety of inflammation related diseases like
cancer, psoriasis and arthritis. Thus, as in many other signal
transduction pathways, there are multiple feedback mechanisms
to balance the activity of NF-kB. A well established mechanism is
NF-kB dependent induction of IkBa which disrupts NF-kB DNA
binding and shuttles nuclear NF-kB back to cytoplasm, thus
forming a negative regulation loop [3,4,5]. A20 is another NF-kB
induced gene that inhibits NF-kB activity by degrading receptor
interacting protein (RIP), an essential mediator for the activation
of the TNF receptor-associated signaling complex in the
cytoplasm [6]. In addition to negative regulation by NF-kB
inducible genes, NF-kB is negatively regulated by CYLD,
a deubiquitinase that represses the activation of the IKK
complex by removing K63-linked ubiquitin chains from TRAFs
and NEMO [7,8,9].
In addition to protein ubiquitination, growing evidence suggests
that several proteins in the NF-kB pathway are regulated by
SUMOylation [10]. SUMOylation is a posttranslational modifi-
cation involving covalent conjugation of small ubiquitin-like
modifier proteins (SUMO) to target proteins. In contrast to
protein ubiquitination, which generally tags proteins for protea-
some-mediated degradation, SUMOylation modulates protein
localization, protein/protein interaction, transcriptional regula-
tion, as well as protein stabilization. SUMOylation of IkBa
inhibits NF-kB activation by blocking IkBa ubiquitination and
degradation [11]. In response to genotoxic stress but not
inflammatory challenge, NF-kB is activated by PIASy-mediated
NEMO SUMOylation [12].
Mammalian PIAS has four family members including PIAS1,
PIAS2 (PIASx), PIAS3, and PIASy [13]. PIAS proteins have four
conserved structural domains and motifs: a SAP domain for
chromatin binding, PINIT motif for localization, SP-RING
domain for E3-SUMO ligation, and a SUMO-interacting motif
for SUMO binding. While PIASy-mediated NEMO SUMOyla-
tion contributes to NF-kB activation [12], PIAS1 and PIAS3
inhibit NF-kB activity by direct binding to the RelA subunit of
NF-kB [14,15]. PIAS1 binds to the C-terminal transactivation
domain of RelA and blocks RelA binding to DNA in vitro and in
vivo [14]. PIAS3 binds to the N-terminal DNA binding domain of
RelA and interferes with RelA binding to the CBP coactivator
[15]. In our previous studies, we also found that PIASy represses
NF-kB activity in mouse keratinocytes and represses the expres-
sion of CCL20 chemokine in response to TNFa and/or IL-17A
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a mechanism for transcriptional repression conserved from yeast
to human [17], RelA SUMOylation and its role in transcriptional
regulation have not been defined.
In this study, we provide in vitro (cell free) and in vivo evidence
that RelA is SUMOylated. RelA is predominantly SUMOylated
by PIAS3, among PIAS family proteins. PIAS3-mediated NF-kB
repression is compromised by either RelA mutant resistant to
SUMOylation or PIAS3 mutant defective in SUMOylation. The
SUMOylation of endogenous RelA by PIAS3 is induced by NF-
kB activation. Furthermore, PIAS3-mediated RelA SUMOylation
was dependent on RelA DNA binding. These data suggest PIAS3-
mediated RelA SUMOylation as a novel negative regulatory
mechanism for NF-kB regulation.
Materials and Methods
Plasmids
Flag-tagged RelA/p65 was constructed by cloning the RelA/
p65 coding sequence from HA-tagged RelA (kindly provided by S.
Ghosh, Yale University) into pCMVTag2B vector (Stratagene).
V5-tagged RelA was constructed by cloning RelA coding sequence
from Flag-tagged RelA vector into pCDNA-v5 vector (Invitrogen).
RelA mutants (121/122K.R, 37K.R, 39E.I, 36Y.A) and
catalytically dead PIAS3 mutant (299C.S) were generated by
targeted mutagenesis (Stratagene). His-tagged RelA and PIAS3
were cloned into pET-24a expression vector for the production of
PIAS3 and RelA recombinant protein in BL-21 E. coli cells. Flag-
tagged Pias1and PIAS3 cDNA were kindly provided by Shaiu Ke,
UCLA. His-tagged SUMO3 and constitutively active IKK2 were
kindly provided by Paul Fraser [18] and Anjana Rao [19],
respectively.
Cell Culture and Transfection
Human embryonic kidney 293T (HEK293T) cells (Invitrogen),
mouse 3T3 fibroblasts [20], IkBa null fibroblasts and wild type
fibroblasts [3,4,5] were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum. Cells were
transfected in serum free OptiMEM medium (Invitrogen) at 90%
confluence using Transfectin (Bio-Rad) according to the manu-
facturer’s instructions.
Expression and Purification of Recombinant Bacterial
Proteins
BL-21 cells containing the 66his- and 66his-Flag expression
vectors noted above were grown to log phase in 300 ml Luria
broth and induced with 1 mM IPTG (Fisher) for 1 hour. The cells
were centrifuged at 5000 rpm for 5 mins at 4uC. The pellet was
diluted in nickel lysis buffer (50 mM NaH2PO4, 300 mM NaCl,
20 mM imidazole, pH 8.0), treated with lysozyme (1 mg/ml) for
20 minutes on ice, and sonicated. The crude lysate was clarified by
centrifugation at 10,000 rpm for 20 min. The lyaste was incubated
with 1 mL of Ni-NTA agarose slurry (Invitrogen) in nickel lysis
buffer for 1 hr at 4uC. The beads were washed three times with
6 ml nickel wash buffer (50 mM NaH2PO4, 300 mM NaCl,
60 mM imidazole, pH 8.0), and eluted in 500 mL fractions using
the nickel elution buffer (50 mM NaH2PO4, 300 mM NaCl,
250 mM imidazole, pH 8.0). The eluants were dialyzed against
DNAB buffer (50 mM NaCl, 20 mM Tris [pH7.2]; 4% glycerol;
0.1% Triton-100; 1 mM EDTA). The purity and concentration of
purified proteins were verified by Coomassie stain and immuno-
blotting.
In vivo SUMOylation Assay
Murine 3T3 cells were transfected with His6-tagged SUMO
vector, V5-tagged RelA vector, and Flag-tagged PIAS vectors, and
other vectors as indicated. 24 hrs after transfection, cells were
washed twice with PBS and harvested in 1 ml of PBS. Fifty
percent of cells collected were lysed in RIPA buffer and used for
direct immunoblotting. The remainder was lysed in denaturing
lysis buffer (6 ml of 6 M guanidinium-HCl, 0.1 M Na2HPO4/
NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 5 mM, imidazole and
10 mM beta-mercaptoethanol). 50 mlo fN i
2+-NTA-agarose beads
(Qiagen) were then added and lysates were rotated at room
temperature (RT) for 4 h. The beads were washed for 5 min
between each step at room temperature with each of the following
buffers, successively: Buffer A (6 M guanidinium-HCl, 0.1 M
Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0 plus 10 mM b-
mercaptoethanol); Buffer B (8 M urea, 0.1 M Na2HPO4/
NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 10 mM b-mercaptoetha-
nol); and Buffer C (8 M urea, 0.1 M Na2HPO4/NaH2PO4,
0.01 M Tris/HCl, pH 6.3, 10 mM b-mercaptoethanol plus 0.2%
Triton X-100). After the last wash His6-tagged SUMOylated
products were eluted by incubating the beads in 75 ml of 200 mM
imidazole, 0.15 M Tris/HCl pH 6.7, 30% glycerol, 0.72 M b-
mercaptoethanol, 5%SDS for 20 min with vigorous shaking. The
eluates were subjected to immunoblotting with anti-RelA antibody
(C-20, Santa Cruz) or anti-V5 antibody (Abcam).
Figure 1. RelA is predominantly SUMOylated by PIAS3. A)
SUMOylation of overexpressed RelA by PIAS proteins. Mouse 3T3
fibroblast cells were transfected with V5-tagged RelA, His-tagged
SUMO3, and Flag-tagged PIAS vectors as indicated. SUMOylated RelA
was measured by in vivo SUMOylation assay with anti-V5 antibody. B)
TNFa-dependent SUMOylation of endogenous RelA in mouse 3T3
fibroblast cells. Mouse 3T3 cells were transfected with His-tagged
SUMO3 and Flag-tagged PIAS vectors as indicated. The cells were
treated with TNFa (20 ng/ml) for 4 hours after overnight transfection.
SUMOylated RelA was measured by in vivo SUMOylation assay with
anti-RelA antibody.
doi:10.1371/journal.pone.0037636.g001
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His-tagged RelA, RelA 122R mutant, and PIAS3 proteins were
produced in BL-21 E. coli transformed with the corresponding
pET-24a expression vectors by IPTG induction for 1 hour at room
temperature. The His-tagged proteins were purified by Ni-NTA
affinity purification in lysis buffer (50 mM NaHPO4 pH8,
300 mM NaCl, 10 mM imidazole). The eluted proteins were
dialyzed against binding buffer (50 mM Tris [pH7.2]; 4%
glycerol; 0.1% Triton-100; 1 mM EDTA; 50 mM NaCl). The in
vitro SUMOylation assay was performed in 40 ml of reaction buffer
(20 mM HEPES [pH 7.4], 50 mM MgCl2, 20 mM ATP) with
0.1 mg of SAE1/SAE2 (Boston Biochem), 0.1 mg of Ubc9 (Boston
Biochem), 6 ug of SUMO3, 15 ng of RelA, and 0.2 mg of PIAS3
at 37C for one hour. The reaction was terminated by 56 SDS
sample buffer. The SUMOylated products were visualized by
immunoblotting with anti-RelA antibody.
Luciferase Assay
Mouse 3T3 cells were plated in 24 well plates and transfected
with NF-kB reporter, and b-galactosidase reporter vectors. 24 hrs
post-transfection, cells were lysed in luciferase assay buffer (0.1 M
NaPO4 [pH 8.0], 4 mM ATP, 1 mM pyrophosphate, 1 mM
MgCl, 20 mM DTT) supplemented with 0.2% Triton-100.
Cleared supernatants were used for luciferase measurement. The
b-galactosidase activity was measured by Tropix galacto-light
beta-galactosidase assay (Applied Biosystems) for data normaliza-
tion. The relative NF-kB luciferase activity was calculated by
dividing the signal of NF-kB reporter by that of b-galactosidase.
His-SUMO3 Lentivirus
His-SUMO3 [18] was cloned into XhoI/EcoRI sites of pSL35
lentiviral vector [21]. His-SUMO3 lentiviruses were generated
using the four-plasmid system by cotransfection of 293T cells with
pSL3, which expresses the vesicular stomatitis virus G envelope
protein; pSL4, which expresses the HIV-1 gag/pol genes; pSL5,
which expresses the rev gene; and pSL35 containing His-SUMO3.
Lentivruses were harvested at 48 and 72 h after the transfection
and concentrated by ultracentrifugation at 500,0006g for 90 min.
The recombinant virus titer was determined for use of minimal
viral particles to achieve $90% infection of IkBa null fibroblasts
and wild type fibroblasts.
DNA Affinity Immunoblot
RelA DNA binding activity was measured by DNA affinity
immunoblotting, a sensitive in vitro technique for measurement of
endogenous DNA binding proteins [22]. A 200 mg aliquot of
nuclear extract was mixed with biotinylated NF-kappaB consensus
binding sequence, biotin-CATAAGTCATGAGTTGAGGG-
GACTTTCCCAGGC in 16 DNA binding buffer [20 mM Tris
(pH 7.2), 1 mM EDTA, and 0.06% Triton X-100 supplemented
with 5 mM DTT, and 10 mg salmon sperm DNA), with a final
NaCl level equal to 250 mM and glycerol level equal to 4%] in
cold room for 30 minutes. The DNA bound proteins were
captured by streptavidin magnasphere paramagnetic particles
(Promega) and analyzed by immunoblotting.
Results
RelA SUMOylation by PIAS3
To determine whether RelA is SUMOylated by PIAS
proteins, we evaluated in vivo RelA SUMOylation in murine
3T3 cells transiently transfected with V5-tagged RelA, Flag-
tagged PIAS proteins, and His-tagged SUMO3. Analysis of
nickel-affinity purified RelA from the cell lysate revealed several
slowly migrating forms of RelA (Figure 1A). As the slowly
migrating forms of RelA were dependent on co-transfection of
his-tagged SUMO3 (Figure S1), they represent SUMOylated
RelA species with one or more SUMO3 molecules. Although
RelA SUMOylation by PIAS1 and PIASy was detectable, PIAS3
showed the most potent effect on RelA SUMOylation. PIAS3-
dependent RelA SUMOylation was also detected in other cell
types such as HEK293 and H1299 cells (Figure S2). To test
whether endogenous RelA is SUMOylated by PIAS3, we
evaluated RelA SUMOylation by in vivo SUMOylation assay in
3T3 cells transiently transfected with Flag-tagged PIAS and His-
tagged SUMO3. The SUMOylation of endogenous RelA by
either PIAS1 or PIASy was barely detectable (Figure 1B). The
endogenous RelA was SUMOylated by PIAS3 only after NF-kB
activation by treatment of cells with TNFa (Figure 1B). Taken
together, these data provide evidence that RelA is SUMOylated
and that RelA SUMOylation is mediated by PIAS3.
Lysine 37, 121/122 are the Major SUMOylation Sites in
RelA
Protein SUMOylation generally targets lysine residues in
a yKXE consensus sequence [23], where y is a hydrophobic
amino acid residue, X represents any residue, E is an acidic
residue, and K is a lysine residue to which SUMO moiety is
covalently bound. There is no perfectly matched yKXE consensus
sequence in RelA protein. However, several nearly matched
Figure 2. Identification of preferred RelA SUMOylation site. A)
Mouse 3T3 cells were transfected with His-tagged SUMO3, v5-tagged
RelA mutants 37R, 122R (121K.R/122K.R), and 222R as indicated, and
Flag-tagged PIAS3 plasmids. The SUMOylated RelA was measured by
nickel pull down followed by immunoblotting with V5 antibody. The
total RelA protein was measured by direct immunoblotting with V5
antibody. B) Analysis of PIAS3-dependent RelA SUMOylation by in vitro
SUMOylation assay. The in vitro SUMOylation assay was conducted with
Purified E1 (SAE1), Ubc9, PIAS3, wild type RelA (wt), and RelA 122R
mutant (122) as indicated. The SUMOylated RelA was detected by
immunoblotting with anti-RelA antibody.
doi:10.1371/journal.pone.0037636.g002
RelA SUMOylation by PIAS3
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37636yKXE consensus sequences in RelA protein are 37K(YKCE),
121/122K (VKKRD), and 222K (QKED). In vivo SUMOylation
analysis of these RelA mutants revealed that PIAS3-mediated
RelA SUMOylation was compromised by RelA mutations from
lysine to arginine at 37 and 121/122 respectively (Figure 2A).
PIAS3-mediated RelA SUMOylation was virtually abolished by
compound mutation of 37K and 121/122K, indicating that lysine
residues at 37 and 121/122 are involved in PIAS3-mediated RelA
SUMOylation. To further define the role of PIAS3 in RelA
SUMOylation, we conducted in vitro SUMOylation assays with
purified RelA and PIAS3 proteins. As expected, RelA SUMOyla-
tion was abolished in the absence of either E1 enzyme (SAE1) or
E2 enzyme (Ubc9) in the in vitro SUMOylation reaction.
Consistent with the in vivo SUMOylation assays and RelA
mutational analysis, RelA SUMOylation in vitro was enhanced
by PIAS3 (Figure 2B) and RelA SUMOylation was compromised
by 121/122 K.R mutation.
RelA SUMOylation Dependent NF-kB Repression
Protein SUMOylation has been associated with a number of
cellular activities including transcriptional repression by altering
protein interactions [24]. To test the effects of PIAS3-mediated
RelA SUMOylation, NF-kB luciferase activity was measured in
293T cells transfected with wild type RelA and SUMO defective
RelA (SD-RelA, RelA with K.R mutations at 37, 121, and 122)
(Figure 3A). NF-kB activation by wild type RelA was significantly
repressed by PIAS3 overexpression. However, PIAS3-dependent
NF-kB repression was compromised in the SUMOylation de-
fective RelA mutant. As lysine is the accept site not only for
SUMOylation but also for acetylation, methylation, and ubiqui-
tination, these modifications may potentially contribute to altered
NF-kB activity of SUMO defective RelA. To further define the
contribution of RelA SUMOylation to NF-kB repression, NF-kB
luciferase activity was compared in 293T cells transfected with
wild type PIAS3 and catalytically dead PIAS3 mutant (CD-PIAS3,
PIAS3 with C.S mutation at 299) (Figure 3B). The catalytically
dead PIAS3 mutant failed to mediate RelA SUMOylation in
response to NF-kB activation by constitutively active IKK2. These
results suggest PIAS3-mediated RelA SUMOylation as a mecha-
nism of NF-kB transcriptional repression.
PIAS3 Mediated RelA SUMOylation is Induced by NF-kB
Activation
Because PIAS3-mediated RelA SUMOylation was associated
with NF-kB inhibition, we evaluated RelA SUMOylation as
a potential mechanism for NF-kB negative regulation after
activation by either TNFa treatment or co-transfection of
constitutively active IKK2. Similar to TNFa treatment, the
SUMOylation of endogenous RelA was induced by IKK2 co-
transfection (Figure 4A). Analysis of NF-kB activity in the
corresponding cells confirmed NF-kB activation by either TNFa
treatment or IKK2 co-transfection (Figure 4B). In addition, the
Figure 3. RelA SUMOylation-mediated NF-kB repression. A) Effects of RelA SUMO-dead mutation on PIAS3-mediated NF-kB repression. HEK
293T cells were transfected with his-tagged SUMO3, v5-tagged SUMO-dead mutant (SD, RelA with K.R mutations at 37, 121, and 122) and its wild
type control (wt) in the presence or absence of Flag-tagged PIAS3. The SUMOylated RelA was measured by in vivo SUMOylation assay with anti-V5
antibody (upper panel). The corresponding NF-kB luciferase activity was measured (lower panel). B) Effects of PIAS3 catalytically dead mutation on
PIAS3 mediated NF-kB repression. HEK 293T cells were transfected with wild type PIAS3 (WT), PIAS3 catalytically dead mutant (CD, PIAS3 with C.S
mutation at 299), in the presence or absence of constitutively active IKK2. The SUMOylation of endogenous RelA was measured by in vivo
SUMOylation assay with anti-RelA antibody (Upper panel). The corresponding NF-kB luciferase activity was measured (lower panel).
doi:10.1371/journal.pone.0037636.g003
RelA SUMOylation by PIAS3
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This suggests that NF-kB activation is required for PIAS3-
mediated RelA SUMOylation. Because NF-kB activation is
repressed by PIAS3, RelA SUMOylation by PIAS3 is likely
a mechanism for NF-kB negative regulation.
To further define the role of NF-kB activation in RelA
SUMOylation, we examined the kinetics of PIAS3-mediated
RelA SUMOylation in response to TNFa treatment. PIAS3-
mediated RelA SUMOylation was observed 150 minutes after
TNFa treatment and increased with time after TNFa treatment
(Figure 4C). These results are consistent with RelA SUMOylation
by PIAS3 as a negative regulatory mechanism for NF-kB.
DNA Binding Dependent RelA SUMOylation by PIAS3
The central mechanism of NF-kB regulation is through the NF-
kB negative regulator, IkBa, which sequesters NF-kB in the
cytoplasm and dissociates NF-kB from DNA in the nucleus [2]. To
further define the role of PIAS3-mediated RelA SUMOylation as
a negative regulator of activated NF-kB in the nucleus, we
evaluated RelA SUMOylation in cells with IkBa null background.
To overcome low transfection frequency of IkBa null cells
compared to wild type cells, we established cell lines with stable
expression of His-tagged SUMO3. In the absence of TNFa, RelA
SUMOylation was barely detected in either wild type or IkBa null
cell lines. RelA SUMOylation was induced in both wild type and
IkBa null cell lines upon TNFa treatment. IkBa null cells showed
much stronger RelA SUMOylationon than its wild type counter-
part (Figure 5A). To test whether enhanced RelA SUMOylation in
IkBa null cells is associated with increased RelA nuclear
accumulation or RelA DNA binding capability, we evaluated
RelA SUMOylation in wild type and IkBa null cells treated with
leptomycin B to block RelA nuclear export. Upon leptomycin B
treatment, RelA accumulated in the nucleus in both wild type and
IkBa null cells (Figure 5). However, RelA SUMOylation was
detected only after TNFa treatment, not in either cell line treated
with leptomycin B alone, showing that nuclear accumulation of
RelA was insufficient for RelA SUMOylation.
Because dissociation of RelA DNA binding is another function
of IkBa, we evaluated whether RelA DNA binding is required for
PIAS3-mediated SUMOylation of RelA by using RelA mutants
(39E.I and 36Y.A) defective in DNA binding [25]. The 39E.I
and 36Y.A mutants, conferred defects in NF-kB activation as
expected (Figure 6A). Consistent with previous DNA binding data
[25], the39E.I and 36Y.A mutants failed to bind NF-kB
consensus DNA binding sequence whereas the DNA binding
activity of 37K.R mutant was not affected (Figure 6B). Com-
pared with wild type RelA and SUMOylation compromised
mutant at 37K, PIAS3-mediated RelA SUMOylation was
abolished by both 39E.I and 36Y.A mutants (Figure 6B). It is
of interest to note that weak RelA SUMOylation was induced
Figure 4. Endogenous RelA SUMOylation by PIAS3 is induced by NF-kB activation. A) HEK 293T were transfected with his-SUMO3 plus
PIAS3 or GFP control plasmid as indicated. NF-kB activation was achieved by either co-transfection of constitutive IKK2 or TNFa treatment (20 ng/ml
for 4 hours). SUMOylated RelA was measured by nickle pull down followed by immunoblotting with anti-RelA antibody. B) NF-kB repression by PIAS3.
The NF-kB activity of cells described in panel A was measured by NF-kB luciferase assay. C) The time course of RelA SUMOylation in response to NF-kB
activiation. HEK 293T cells were transfected with his-SUMO3 plus PIAS3 or control GFP plasmid as indicated. The cell lysates were collected for in vivo
SUMOylation assay at indicated time points after TNFa treatment (20 ng/ml). SUMOylated RelA was detected by nickel pull down followed by
immunoblotting with anti-RelA antibody.
doi:10.1371/journal.pone.0037636.g004
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due to the generation a perfectly matched SUMO consensus site
(yKXE), converting a polar amino acid to a hydrophobic amino
acid. Even so, PIAS3-dependent RelA SUMOylation was
abolished by the same mutation. The abolition of PIAS3-mediated
RelA SUMOylation by different RelA mutants defective in DNA
binding suggests that DNA bound RelA is the preferred target for
SUMOylation by PIAS3.
Discussion
NF-kB is known to be tightly negatively regulated by IkBa,
which dissociates NF-kB from DNA and sequesters it in the
cytoplasm [3,4,5,26]. In this study, we provide experimental
evidence for a novel mechanism for negative regulation of NF-kB
by PIAS3-mediated RelA SUMOylation. PIAS3-mediated SU-
MOylation of endogenous RelA was observed to increase with
time after TNFa stimulation, and RelA DNA binding-defective
mutants were resistant to PIAS3-mediated SUMOylation. The
dependence of SUMOylated RelA upon DNA binding capability
as shown by DNA binding defective mutants, and upon TNFa
stimulation and not simply nuclear localization after leptomycin B
treatment, suggests a biochemical mechanism for NF-kB tran-
scriptional repression.
PIAS3 has been reported to repress NF-kB activity through
interfering with RelA binding to transcriptional co-activators [15].
However, PIAS3-mediated RelA SUMOylation was not consid-
ered a factor, largely due to the lack of perfectly matched SUMO
consensus motifs in the RelA protein sequence and lack of
detectable SUMOylated RelA under the conditions of that study.
In our study, we demonstrate RelA SUMOylation by PIAS3
under both overexpressed and physiological conditions. While
RelA could be weakly SUMOylated by other PIAS proteins like
PIAS1 and PIASy, endogenous RelA was SUMOylated specifi-
cally by PIAS3, indicating PIAS3 as a primary mediator for RelA
SUMOylation. Approaches to knockdown PIAS3 function by
shRNA targeting of PIAS3 have been unsuccessful, so far, to
address PIAS3dependence of RelA SUMOylation, in part possibly
due to PIAS redundancy and shRNA efficiency. However,
endogenous RelA SUMOylation specifically mediated by PIAS3
was demonstrated using the catalytically dead PIAS3 mutant.
Although protein SUMOylation is associated with many cellular
activities, transcriptional repression is the primary consequence of
protein SUMOylation. In fact, SUMO consensus sequence
(yKXE) was identified as a synergy control motif for transcrip-
tional repression even before being recognized as a SUMO
consensus sequence [27]. The identification of RelA SUMOyla-
tion has been hampered by the lack of perfectly matched yKXE
consensus sequence in RelA protein [15]. Recent global analysis of
SUMOylated endogenous proteins revealed that one third of
SUMO sites are not perfectly matched to yKXE consensus
sequences [28]. In this study, we have identified two imperfectly
matched SUMOylation sites, 37K (YKCE), 121/122K (VKKRD)
in RelA protein. Compound mutation of these sites abolished
PIAS3-mediated RelA SUMOylation, and compromised PIAS3-
mediated NF-kB repression (Figure 2 and Figure 3). Compromised
NF-kB repression by PIAS3 mutant defective in E3 SUMO ligase
activity further supported the role of PIAS3-mediated RelA
SUMOylation in NF-kB repression (Figure 3B). These data
suggest that RelA SUMOylation is a mechanism for NF-kB
Figure 5. PIAS3-mediated RelA SUMOylation is enhanced by IkBa deficiency. IkBa null and wild type fibroblasts were stably transduced
with His-tagged SUMO3 lentivirus. The SUMO3 transduced cells were treated with 20 ng/ml TNFa for 2 hours without (A) or with (B) 10 ug/ml
leptomycin B for 2 hours, and subjected to in vivo SUMOylation assay. The SUMOylated RelA was detected by immunobloting with anti-RelA
antibody. C) RelA localization in response to TNFa and/or leptomycin B treatment. RelA protein was stained with anti-RelA antibody. The bar equals
20 microns.
doi:10.1371/journal.pone.0037636.g005
RelA SUMOylation by PIAS3
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tion in transcriptional repression.
So far, the mechanism of RelA SUMOylation-mediated
transcriptional repression is largely unknown. A number of
transcriptional repressors and corepressors are either SUMOy-
lated or associated with SUMOylated proteins through their
SUMO interacting motif, thus enabling formation of transcription
repression complexes [17,26]. SUMOylation contributes to
heterochromatin establishment and maintenance in yeast and
Drosophila [29,30]. A number of transcriptional repressors are
either SUMOylated or capable of binding to the SUMO moiety
through the SUMO interacting motif (SIM), including HDAC1
[31], CtBP [32], ZEB1 [26] and CoREST [33]. However, it has
been a challenge to identify SUMOylation-dependent formation
of transcription repression complexes. By sequential chromatin
immunoprecipitation, Shuai’s group elegantly demonstrated
PIAS1-dependent recruitment of heterochromatin protein 1 and
DNA methyltransferase to the Foxp3 promoter [34]. These lines
of evidence suggest that PIAS3-mediated RelA SUMOylation may
provide a scaffold for the recruitment of transcriptional repressors
with SUMO binding motifs thus leading to transcriptional
repression. In addition to SUMOylation, the RelA SUMO sites
are modified by methylation by SET7/9 [35] and acetylation by
p300 and PCAF [36]. Further study to understand the relationship
among these modifications is needed to define the mechanism of
RelA SUMOylation in NF-kB transcriptional regulation.
Like many important signaling pathways, the NF-kB pathway is
exquisitely regulated by multiple negative feedback regulatory
mechanisms, such as the induction of IkBa to sequester NF-kBi n
the cytoplasm [5] and A20 to block NEMO activation [37]. In
addition to NF-kB repression by RelA SUMOylation, we also
demonstrated that PIAS3-mediated RelA SUMOylation was
induced by NF-kB activation (Figure 5). The induction of RelA
SUMOylation by NF-kB activation and the repression of NF-kB
activity by RelA SUMOylation suggest that PIAS3-mediated RelA
SUMOylation is a negative feedback mechanism for NF-kB
regulation. This notion was further supported by the evidence
from IkBa null cells, in which RelA SUMOylation was
significantly enhanced, suggesting its compensatory role in NF-
kB negative regulation.
It remains a challenge to define the molecular pathways that
lead to RelA SUMOylation in response to NF-kB activation. The
evidence from RelA mutants defective in DNA binding suggests
that DNA-bound RelA is the preferred target for PIAS3-mediated
RelA SUMOylation. In this study, RelA mutants (39E.I and
36Y.A) defective in DNA binding [25] also abolished PIAS3-
mediated SUMOylation. Coincidently, both mutations reside in
the N-terminal RelA SUMO consensus motif (36YKCE39). The
abolition of PIAS3-mediated RelA SUMOylation by these
mutations is very unlikely due to the disruption of the SUMO
consensus site. Compared with the SUMOylation of 37K.R
mutant, 39E.I mutation showed more severe effect on PIAS3-
mediated RelA SUMOylation. Furthermore, 36Y.A mutation
that generates a perfect SUMOylation motif, also abolished
PIAS3-mediated RelA SUMOylation despite its enhancement of
PIAS3-independent RelA SUMOylation. The abolition of PIAS3-
mediated RelA SUMOylation by these various RelA DNA
binding mutants suggests that RelA DNA binding is a determining
factor in PIAS3-mediated RelA SUMOylation. In vitro, RelA DNA
complex can be rapidly dissociated by IkBa, which reduces the
half-life of the RelA DNA complex from 45 to 3 minutes [38].
RelA binding to DNA is negatively regulated by IkBa [3], which
therefore reduces the pool of DNA-bound RelA available for
SUMOylation. In the absence of IkBa negative regulation,
increased DNA-bound RelA is available for SUMOylation. Thus,
SUMOylation of RelA could be a mechanism to halt sustained
NF-kB activation that is beyond the capacity of IkBa to control.
The SUMOylation of DNA-bound RelA provides a molecular
basis to form heterchromatic foci at promoters of genes regulated
by NF-kB, to repress transcription, thus safeguarding against
sustained transcriptional activation. Future studies will be needed
to illustrate the mechanisms of RelA SUMOylation in NF-kB
negative regulation in specific cell contexts, including defining NF-
kB downstream genes affected by SUMOylation of RelA, and the
associated transcriptional repressors in complex with SUMOylated
RelA.
Supporting Information
Figure S1 PIAS3 mediated RelA SUMOylation is SU-
MO3 dependent. 293T cells were transfected with v5 tagged
RelA, flag-tagged PIAS, and his-tagged SUMO3 as indicated.
Figure 6. PIAS3-mediated RelA SUMOylation is dependent on
RelA DNA binding. A) HEK 293T cells were transfected with Flag-
tagged PIAS3, V5-tagged RelA and RelA mutants defective in DNA
binding (39I and 36A) as indicated. The transactivation activity was
measured by NF-kB luciferase activity. B) The nuclear extracts from HEK
293T cells transfected with indicated plasmids were subjected to DNA
affinity immunoblotting with biotinylated NF-kB consensus binding
DNA. DNA bound RelA was measured by immunoblotting with anti V5
antibody. C) The cell lysates from HEK293T cells transfected with
indicated RelA mutants were collected for in vivo SUMOylation assay
and detected by anti-V5 antibody for SUMOylated RelA (B).
doi:10.1371/journal.pone.0037636.g006
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immunoblotting with anti-V5 antibody.
(DOCX)
Figure S2 RelA SUMOylation by PIAS3 in HEK293 and
H1299 cells. HEK293 cells (A) or H1299 cells (B) were
transfected with V5-tagged RelA, His-tagged SUMO3, and
Flag-tagged PIAS vectors as indicated. SUMOylated RelA was
measured by nickle pull down followed by immunoblotting with
anti-V5 antibody.
(DOCX)
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